Interim analysis of an open-label extension study of sustained release fampridine in patients with multiple sclerosis

被引：0
|
作者：
Goodman, A. D.
Brown, T.
Krupp, L.
Schapiro, R.
Marinucci, L.
Cohen, R.
Blight, A.
机构：
来源：
MULTIPLE SCLEROSIS | 2009年 / 15卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S13 / S13
页数：1
相关论文
共 50 条
  • [31] Predictors of Relapse in Ozanimod-Treated Patients With Multiple Sclerosis: Post Hoc Analysis From the Open-Label Extension DAYBREAK Study
    Coyle, Patricia
    Dunn, Jeffrey
    Kappos, Ludwig
    Sheffield, James
    Riolo, Jon
    Cheng, Chun-Yen
    Thorpe, Andrew
    Filippi, Massimo
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 1036 - 1037
  • [32] RAISE-XT: An interim analysis of safety and efficacy in an open-label extension study of zilucoplan in patients with myasthenia gravis
    Freimer, Miriam
    Leite, M. Isabel
    Genge, Angela
    Hussain, Yessar
    Kaminski, Henry J.
    Mantegazza, Renato
    Utsugisawa, Kimiaki
    Vu, Tuan
    Duda, Petra W.
    Boroojerdi, Babak
    Vanderkelen, Mark
    Lowcock, Romana
    Howard, James F., Jr.
    NEUROLOGY, 2023, 100 (17)
  • [33] SIMVASTATIN IN SYSTEMIC SCLEROSIS PATIENTS - AN OPEN-LABEL STUDY
    Ionitescu, S. C.
    Mihai, C.
    Bojinca, M.
    Sfrent-Cornateanu, R.
    Ion, A.
    Macovei, L.
    Manea, O.
    Sasu, M.
    Ancuta, I.
    Milicescu, M.
    Mogosan, C.
    Abobului, M.
    Berghea, F.
    Predeteanu, D.
    Ionescu, R.
    Stoica, V.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : S158 - S158
  • [34] Safety of lurasidone in adolescents with schizophrenia: interim analysis of a 24-month, open-label extension study
    Correll, C. U.
    Arango, C.
    Tocco, M.
    Goldman, R.
    Cucchiaro, J.
    Deng, L.
    Loebel, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S1099 - S1099
  • [35] SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY
    Tocco, M.
    Correll, C.
    Goldman, R.
    Cucchiaro, J.
    Deng, L.
    Loebel, A.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2018, 52 : 154 - 155
  • [36] SAFETY OF LURASIDONE IN ADOLESCENTS WITH SCHIZOPHRENIA: INTERIM ANALYSIS OF A 24-MONTH, OPEN-LABEL EXTENSION STUDY
    Tocco, M.
    Correll, C.
    Goldman, R.
    Cucchiaro, J.
    Deng, L.
    Loebel, A.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2018, 52 : 136 - 136
  • [37] Effectiveness of lurasidone in adolescents with schizophrenia: interim analysis of a 24-month, open-label extension study
    Tocco, M.
    Arango, C.
    Correll, C. U.
    Goldman, R.
    Cucchiaro, J.
    Deng, L.
    Loebel, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2017, 27 : S1100 - S1101
  • [38] Results of an open-label extension trial of sativex (THC:CBD) in patients with multiple sclerosis and symptoms of spasticity
    Collin, C.
    Serpell, M.
    Potts, R.
    MULTIPLE SCLEROSIS, 2007, 13 : S129 - S129
  • [39] Safety patterns with ozanimod in phase 3 and open-label extension trials in patients with relapsing multiple sclerosis
    Selmaj, K. W.
    Ziemssen, T.
    Comi, G.
    Hartung, H. P.
    Singal, M.
    Thorpe, A.
    Riolo, J. V.
    Cheng, C. Y.
    Sheffield, J. K.
    Krakovich, A.
    Vermersch, P.
    Cree, B. A. C.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 324 - 324
  • [40] AN OPEN-LABEL STUDY OF SUBCUTANEOUS EVOGAM IN PATIENTS WITH PRIMARY IMMUNODEFICIENCY (PID): INTERIM ANALYSIS
    Stephens, Simone
    Empson, Marianne
    Fitzharris, Penny
    Rozen, Leon
    Pearce, Lisa
    INTERNAL MEDICINE JOURNAL, 2011, 41 : 19 - 20
12345